CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
Lofexidine (granules for reconstitution) +1 moredrug
Likely dose
Lofexidine (granules for reconstitution) 0.36 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04188730
NCT04188730Phase 1Completed

A Study to Evaluate the Relative Bioavailability of a Test Formulation of Lofexidine Granules for Reconstitution and the Effect of Food on the Bioavailability of the Test Formulation in Healthy Adult Subjects

USWM, LLC (dba US WorldMeds)·interventional·Posted Dec 6, 2019·Updated Jun 15, 2022

In Brief

A Phase 1 clinical trial evaluating Lofexidine (granules for reconstitution) and LUCEMYRA (lofexidine) tablets for Normal Healthy Volunteers. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this open-label, single-dose, randomized, three-treatment, three-period, four-sequence, crossover study is to evaluate the relative bioavailability of a test formulation of lofexidine granules for reconstitution (oral) and LUCEMYRA tablets under fasted conditions and to evaluate the effect of food on the relative bioavailability of lofexidine granules for reconstitution (oral) when administered under fed compared to fasted conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedDec 6, 2019
Enrollment StartFeb 16, 2021
Primary CompletionMar 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.6 years ago

Interventions

Lofexidine (granules for reconstitution)drug

All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.

LUCEMYRA (lofexidine) tabletsdrug

All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.